Tags

Type your tag names separated by a space and hit enter

[Pharmacotherapy of severe acute respiratory syndrome (SARS)].
Pneumologie. 2006 Nov; 60(11):694-700.P

Abstract

Severe acute respiratory syndrome (SARS) constitutes the first new infectious disease of the current millennium. It is caused by the novel SARS-Coronavirus (SARS-CoV). SARS is related to a high morbidity and mortality and first appeared during an epidemic in 2002 - 2003. To date no specific therapy against the SARS-CoV is available. Due to the rapid spread of SARS during the epidemics in 2002 - 2003, randomised and controlled multicentre studies were not performed. Therefore, general guidelines have not been developed. Since the outbreak, scientists have been testing potential antiviral substances using in vitro and animal models. This study analyses the presently available in vitro and in vivo data on the pharmacotherapy of SARS.

Authors+Show Affiliations

Abteilung Pneumologie, Zentrum Innere Medizin, Medizinische Hochschule Hannover.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ger

PubMed ID

17109267

Citation

von Hagen, L, et al. "[Pharmacotherapy of Severe Acute Respiratory Syndrome (SARS)]." Pneumologie (Stuttgart, Germany), vol. 60, no. 11, 2006, pp. 694-700.
von Hagen L, Pletz MW, Dickgreber N, et al. [Pharmacotherapy of severe acute respiratory syndrome (SARS)]. Pneumologie. 2006;60(11):694-700.
von Hagen, L., Pletz, M. W., Dickgreber, N., Golpon, H., Bauer, T. T., Zabel, P., Welte, T., & Groneberg, D. A. (2006). [Pharmacotherapy of severe acute respiratory syndrome (SARS)]. Pneumologie (Stuttgart, Germany), 60(11), 694-700.
von Hagen L, et al. [Pharmacotherapy of Severe Acute Respiratory Syndrome (SARS)]. Pneumologie. 2006;60(11):694-700. PubMed PMID: 17109267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacotherapy of severe acute respiratory syndrome (SARS)]. AU - von Hagen,L, AU - Pletz,M W, AU - Dickgreber,N, AU - Golpon,H, AU - Bauer,T T, AU - Zabel,P, AU - Welte,T, AU - Groneberg,D A, PY - 2006/11/17/pubmed PY - 2007/1/31/medline PY - 2006/11/17/entrez SP - 694 EP - 700 JF - Pneumologie (Stuttgart, Germany) JO - Pneumologie VL - 60 IS - 11 N2 - Severe acute respiratory syndrome (SARS) constitutes the first new infectious disease of the current millennium. It is caused by the novel SARS-Coronavirus (SARS-CoV). SARS is related to a high morbidity and mortality and first appeared during an epidemic in 2002 - 2003. To date no specific therapy against the SARS-CoV is available. Due to the rapid spread of SARS during the epidemics in 2002 - 2003, randomised and controlled multicentre studies were not performed. Therefore, general guidelines have not been developed. Since the outbreak, scientists have been testing potential antiviral substances using in vitro and animal models. This study analyses the presently available in vitro and in vivo data on the pharmacotherapy of SARS. SN - 0934-8387 UR - https://www.unboundmedicine.com/medline/citation/17109267/[Pharmacotherapy_of_severe_acute_respiratory_syndrome__SARS_]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2006-944278 DB - PRIME DP - Unbound Medicine ER -